ES2143049T3 - Formas sublinguales de dosificacion que contienen apomorfina y su uso para el tratamiento de la disfuncion erectil. - Google Patents

Formas sublinguales de dosificacion que contienen apomorfina y su uso para el tratamiento de la disfuncion erectil.

Info

Publication number
ES2143049T3
ES2143049T3 ES95916467T ES95916467T ES2143049T3 ES 2143049 T3 ES2143049 T3 ES 2143049T3 ES 95916467 T ES95916467 T ES 95916467T ES 95916467 T ES95916467 T ES 95916467T ES 2143049 T3 ES2143049 T3 ES 2143049T3
Authority
ES
Spain
Prior art keywords
erectile dysfunction
treatment
dosage forms
forms containing
sublingual dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95916467T
Other languages
English (en)
Inventor
Ragab El-Rashidy
Jeremy P W Heaton
Alvaro Morales
Michael A Adams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Queens University at Kingston
Pentech Pharmaceuticals Inc
Original Assignee
Queens University at Kingston
Pentech Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22868404&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2143049(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Queens University at Kingston, Pentech Pharmaceuticals Inc filed Critical Queens University at Kingston
Application granted granted Critical
Publication of ES2143049T3 publication Critical patent/ES2143049T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LA IMPOTENCIA PSICOGENICA O DISFUNCION ERECTIL PUEDE IDENTIFICARSE EN PACIENTES MASCULINOS PSICOGENICOS Y PUEDE MEJORARSE, SIN EFECTOS SECUNDARIOS INDESEADOS IMPORTANTES, MEDIANTE LA ADMINISTRACION SUBLINGUAL DE FORMAS DE DOSIFICACION DE APOMORFINA QUE CONTIENEN ENTRE 2.5 Y 10 MILIGRAMOS DE APOMORFINA Y SU DISOLUCION DURANTE UN PERIODO DE ENTRE 2 Y 5 MINUTOS.
ES95916467T 1994-04-22 1995-04-21 Formas sublinguales de dosificacion que contienen apomorfina y su uso para el tratamiento de la disfuncion erectil. Expired - Lifetime ES2143049T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23125094A 1994-04-22 1994-04-22

Publications (1)

Publication Number Publication Date
ES2143049T3 true ES2143049T3 (es) 2000-05-01

Family

ID=22868404

Family Applications (2)

Application Number Title Priority Date Filing Date
ES99121684T Expired - Lifetime ES2256999T3 (es) 1994-04-22 1995-04-21 Composcion sublingual que contiene apomorfina para el diagnostico de la impotencia funcional.
ES95916467T Expired - Lifetime ES2143049T3 (es) 1994-04-22 1995-04-21 Formas sublinguales de dosificacion que contienen apomorfina y su uso para el tratamiento de la disfuncion erectil.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES99121684T Expired - Lifetime ES2256999T3 (es) 1994-04-22 1995-04-21 Composcion sublingual que contiene apomorfina para el diagnostico de la impotencia funcional.

Country Status (15)

Country Link
US (3) US5770606A (es)
EP (2) EP0758895B1 (es)
JP (1) JP3310982B2 (es)
KR (1) KR100374924B1 (es)
AT (2) ATE312609T1 (es)
AU (1) AU703608B2 (es)
CA (1) CA2188385C (es)
DE (3) DE10199068I2 (es)
DK (2) DK0978282T3 (es)
ES (2) ES2256999T3 (es)
GR (1) GR3033084T3 (es)
LU (1) LU90856I2 (es)
NL (1) NL300072I1 (es)
PT (1) PT758895E (es)
WO (1) WO1995028930A1 (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US20020165122A1 (en) * 1994-04-22 2002-11-07 Heaton Jeremy P. W. Method and compositions for the treatment or amelioration of female sexual dysfunction
US6121276A (en) * 1994-04-22 2000-09-19 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
US6566368B2 (en) * 1994-04-22 2003-05-20 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage form for ameliorating male erectile dysfunction
US6395744B1 (en) 1994-04-22 2002-05-28 Queen's University At Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5888534A (en) * 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
AU751565B2 (en) * 1995-06-13 2002-08-22 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
US20050065161A1 (en) * 1996-02-02 2005-03-24 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
EP0834308A1 (en) * 1996-09-30 1998-04-08 LG Chemical Limited Ophthalmic formulation for treating myopia comprising dopamine agonist and cyclodextrin
DE19652268C2 (de) * 1996-12-16 2000-06-29 Lohmann Therapie Syst Lts Arzneizubereitung für die Freisetzung von Apomorphin in der Mundhöhle
GB9700878D0 (en) * 1997-01-17 1997-03-05 Scherer Ltd R P Dosage forms and method for ameliorating male erectile dysfunction
US6043252A (en) * 1997-05-05 2000-03-28 Icos Corporation Carboline derivatives
EP0996447B1 (en) * 1997-05-19 2006-07-19 Zonagen, Inc. Combination therapy for modulating the human sexual response
CN1309561A (zh) * 1997-05-29 2001-08-22 持田制药株式会社 勃起机能障碍治疗剂
WO1999002147A1 (en) 1997-07-09 1999-01-21 Androsolutions, Inc. Improved methods and compositions for treating male erectile dysfunction
US6103765A (en) 1997-07-09 2000-08-15 Androsolutions, Inc. Methods for treating male erectile dysfunction
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
EP1035833B1 (en) * 1997-12-02 2005-08-31 Archimedes Development Limited Compositions for nasal administration
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
AU2003204720B2 (en) * 1998-05-29 2006-06-29 Tap Pharmaceutical Products Inc. Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
US6403605B1 (en) * 1998-05-29 2002-06-11 Queen's University At Kingston Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
US20020002175A1 (en) * 2000-09-19 2002-01-03 Charanjit Behl Nasal delivery of apomorphine in combination with glycol derivatives
US6436950B1 (en) 1998-08-14 2002-08-20 Nastech Pharmaceutical Company, Inc. Nasal delivery of apomorphine
US5994363A (en) * 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
US20040063719A1 (en) * 1998-08-26 2004-04-01 Queen's University At Kingston Combination therapy using antihypertensive agents and endothelin antagonists
CA2340206A1 (en) * 1998-08-26 2000-03-09 Queen's University At Kingston Use of anti-pressor agents for vascular remodeling in genital dysfunction
US6291471B1 (en) * 1998-12-17 2001-09-18 Abb Holdings, Inc. Use of apomorphine for the treatment of organic erectile dysfunction in males
US6455564B1 (en) 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
WO2000054773A1 (en) * 1999-03-12 2000-09-21 Nitromed, Inc. Dopamine agonists in combination with nitric oxide donors, compositions and methods of use
US6087362A (en) * 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition
US7577475B2 (en) * 1999-04-16 2009-08-18 Cardiocom System, method, and apparatus for combining information from an implanted device with information from a patient monitoring apparatus
US7258850B2 (en) * 1999-05-04 2007-08-21 Aradigm Corporation Methods and compositions for treating erectile dysfunction
PL211402B1 (pl) * 1999-09-03 2012-05-31 Apbi Holdings Zastosowanie dapoksetyny do leczenia lub zwalczania przedwczesnej ejakulacji
US6506765B2 (en) 2000-04-07 2003-01-14 Tap Pharmaceutical Products, Inc. Apomorphine derivatives and methods for their use
US7223406B2 (en) * 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
WO2002007757A2 (en) * 2000-07-21 2002-01-31 Lue Tom F Prevention and treatment of sexual arousal disorders
FR2813193B1 (fr) * 2000-08-25 2003-08-15 Pelvipharm Medicament pour le traitement des dysfonctions sexuelles par action sur le systeme nerveux central
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
JP2004513899A (ja) 2000-11-15 2004-05-13 タツプ・フアーマシユーテイカル・プロダクツ・インコーポレイテツド 抗鬱薬誘発性的機能不全のアポモルヒネによる治療
US20020103105A1 (en) * 2000-11-22 2002-08-01 Brioni Jorge D. Use of selective dopamine D4 receptor agonists for treating sexual dysfunction
EP1224933A1 (en) * 2001-01-19 2002-07-24 Sanofi-Synthelabo New combination of active ingredients containing alfuzosine and apomorphine
EP1365740A1 (en) * 2001-02-08 2003-12-03 Pharmacia Corporation Rapid-onset medicament for the treatment of sexual dysfunction
US20030187011A1 (en) * 2001-12-20 2003-10-02 Lashuel Hilal A. Apomorphine inhibitors of amyloid-beta (Abeta) fibril formation and their use in amyloidosis based disease
DK1471890T3 (da) * 2002-02-07 2007-01-08 Pharmacia Corp Farmaceutisk doseringsform til mukös afgivelse
KR20050008658A (ko) * 2002-03-19 2005-01-21 마이클 홀릭 아포모르핀의 글리코시드 및 오르토에스테르 글리코시드유도체들, 유사체들 및 그것의 용도
PT2561860T (pt) * 2002-05-31 2018-05-08 Titan Pharmaceuticals Inc Dispositivo polimérico implantável para a libertação prolongada de buprenorfina
GB0221711D0 (en) * 2002-09-19 2002-10-30 Ardana Bioscience Ltd Methods
CA2445212A1 (en) * 2002-10-10 2004-04-10 Queen's University At Kingston Treatment of sexual dysfunction
GB0304636D0 (en) * 2003-02-28 2003-04-02 Britannia Pharmaceuticals Ltd Pharmaceutical composition for nasal delivery
US7943632B2 (en) * 2003-03-17 2011-05-17 Neurohealing Pharmaceuticals, Inc. High potency dopaminergic treatment of neurological impairment associated with brain injury
CA2520613C (en) 2003-03-31 2012-12-04 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of dopamine agonist
RU2364400C2 (ru) * 2003-04-14 2009-08-20 Вектура Лтд Фармацевтические композиции
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
ES2332724T3 (es) * 2003-06-17 2010-02-11 Janssen Pharmaceutica Nv Espirobenzoazepinas sustituidas.
SI1937276T1 (sl) 2005-10-12 2013-04-30 Unimed Pharmaceuticals, Llc C/O Abbott Laboratoires 100 Abbott Park Road Izboljšani testosteronski gel in postopek uporabe
JP2009523806A (ja) * 2006-01-20 2009-06-25 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ （４ｒ）−１−［４−（２−クロロ−５−フルオロベンゾイル）アミノ−３−メトキシベンゾイル］−１，２，３，５−テトラヒドロ−スピロ［４ｈ−１−ベンズアゼピン−４，１’−［２］シクロペンテン］−３’−カルボン酸の新規固体形態物
GB2437488A (en) * 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
RU2391095C1 (ru) * 2009-02-05 2010-06-10 Закрытое акционерное общество "Березовский фармацевтический завод" Фармацевтическая композиция, включающая холина альфосцерат и гопантеновую кислоту (или ее соль), для лечения недостаточности кровообращения мозга и эректильной дисфункции
PT2952191T (pt) 2009-06-12 2018-11-30 Sunovion Pharmaceuticals Inc Apomorfina sublingual
EP2651357B1 (en) 2010-12-16 2020-04-01 Sunovion Pharmaceuticals Inc. Sublingual films
JP2016535794A (ja) * 2013-11-11 2016-11-17 インパックス ラボラトリーズ，インコーポレーテッド 急速崩壊性製剤及びその使用法
MX2016016311A (es) * 2014-06-12 2017-10-12 Univ Notre Dame Du Lac Composición y método para el tratamiento de enfermedades neurológicas y lesión cerebral.
EP4578461A3 (en) 2015-04-21 2025-09-03 Sumitomo Pharma America, Inc. Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa
EP3935581A4 (en) 2019-03-04 2022-11-30 Iocurrents, Inc. DATA COMPRESSION AND COMMUNICATION USING MACHINE LEARNING

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2818855A (en) * 1954-02-11 1958-01-07 Anthony P Miller Surgical device
US4127118B1 (en) * 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4543256A (en) * 1982-03-17 1985-09-24 Northeastern University (-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers
US4687773A (en) * 1983-03-28 1987-08-18 Mclean Hospital (+)-N-N-propylnorapomorphine and selective limbic activity
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4801587A (en) * 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5242391A (en) * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
DE69434304T2 (de) * 1993-03-26 2005-12-29 Merkus, Franciscus Wilhelmus H.M. Pharmazeutische Zusammensetzungen zur intranasalen Verabreichung von Dihydroergotamin

Also Published As

Publication number Publication date
DK0758895T3 (da) 2000-06-13
KR970702041A (ko) 1997-05-13
JP3310982B2 (ja) 2002-08-05
PT758895E (pt) 2000-05-31
AU703608B2 (en) 1999-03-25
DE69534693T2 (de) 2006-08-31
ES2256999T3 (es) 2006-07-16
DK0978282T3 (da) 2006-04-10
DE10199068I2 (de) 2004-05-06
ATE189121T1 (de) 2000-02-15
EP0758895A4 (en) 1997-04-09
HK1014239A1 (en) 1999-09-24
WO1995028930A1 (en) 1995-11-02
CA2188385C (en) 2000-07-11
KR100374924B1 (ko) 2003-07-22
US5985889A (en) 1999-11-16
EP0978282A2 (en) 2000-02-09
NL300072I1 (nl) 2002-02-01
DE69514794D1 (de) 2000-03-02
EP0978282B1 (en) 2005-12-14
JPH09512273A (ja) 1997-12-09
LU90856I2 (fr) 2002-01-24
HK1025742A1 (en) 2000-11-24
EP0758895A1 (en) 1997-02-26
AU2295895A (en) 1995-11-16
DE69534693D1 (de) 2006-01-19
DE69514794T2 (de) 2000-07-27
EP0978282A3 (en) 2000-06-07
US5770606A (en) 1998-06-23
ATE312609T1 (de) 2005-12-15
US6200983B1 (en) 2001-03-13
GR3033084T3 (en) 2000-08-31
EP0758895B1 (en) 2000-01-26
DE10199068I1 (de) 2003-06-05
CA2188385A1 (en) 1995-11-02

Similar Documents

Publication Publication Date Title
DK0758895T3 (da) Sublinguale dosisformer indeholdende apomorphin til anvendelse ved behandling af erektil dysfunktion
MX9703868A (es) Inhibidores de cgmp-pde para el tratamiento de disfuncion erectil.
BR9911408A (pt) Formas de dosagem contendo apomorfina paramelhora de disfunção erétil masculina
WO1994004120A3 (en) Methods of treating sexual dysfunction in animals with and h agonist
MX9700534A (es) Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para tratar las enfermedades de prostata, endometriosis y obesidad.
ES2154741T3 (es) Uso de agentes de union a cd23 en el tratamiento de enfermedades autoinmunes.
PT907652E (pt) Compostos e processos imunossupressores
ZA200104146B (en) Use of apomorphine in the manufacture of a medicament for the treatment of organic erectile dysfunction in males.
DE68921342D1 (de) Versorgungsleitungsanordnung und -vorrichtung für ultrareines wasser.
BR9807523A (pt) Quinoxalinas em combinação tripla com inibidores da protease e inibidores de transcriptase reversa como medicamentos para o tratamento de aids.
DK0663835T3 (da) Anvendelse af parathormon, dets biologisk aktive fragmenter og relaterede peptider til behandling af graviditet
ID24184A (id) Obat untuk perawatan disfungsi ereksi
MX9302378A (es) Antagonistas de serotonina.
ITMI932412A1 (it) Uso di alfa 1-bloccanti nel trattamento della eiaculazione precoce
UY27031A1 (es) Uso de agonistas selectivos del receptor de dopamina d4 para tratar disfunción sexual
PL371131A1 (en) Use of a combination composition comprising propionyl l-carnitine and further drugs for the treatment of erectile dysfunction
AR019327A1 (es) Combinacion de fentolamina y apomorfina para el tratamiento de la funcion y disfuncion sexual humana
MXPA02012911A (es) Compuestos de rutenio (ii) para el uso en terapia del cancer.
ES2163833T3 (es) Procedimiento y linea de tratamiento para la fabricacion de bandas metalicas con superficies de la banda descascarilladas.
ES2183814T3 (es) Composicion farmaceutica que contiene il-6 y su uso para el tratamiento del trastorno trombohemorragico de consumo.
AR244073A1 (es) Dispositivo para el tratamiento de la disfuncion sexual masculina.
DE69426986D1 (de) Behandlung von laminitis
CA2158425A1 (en) Diagnostic and treatment of erectile dysfunction
FI952018A7 (fi) BHAP-yhdisteiden käyttö yhdessä muiden ei-nukleosidi-käänteistransskri ptaasi-inhibiittoreiden kanssa HIV-infektion hoitoon
ES2092685T3 (es) Uso de atipamezol para el tratamiento de impotencia sexual masculina.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 758895

Country of ref document: ES

SPCF Request for supplementary protection certificate filed

Free format text: HIDROCLORURO DE APOMORFINA (UPRIMA)

Spc suppl protection certif: C200100046

Filing date: 20011128

SPCG Supplementary protection certificate granted

Free format text: HIDROCLORURO DE APOMORFINA (UPRIMA)

Spc suppl protection certif: C200100046

Filing date: 20011128

Expiry date: 20160528

Effective date: 20040309